Help us improve Portfolio Grader.

Help us improve Portfolio Grader.

Blue Chip Growth

Stock Report: Lipocine, Inc. (LPCN) Report Updated: Jun 16, 2018 | Print This Page

Get more stock ratings by Louis Navellier

Lipocine, Inc. (LPCN)

Rating: Sell Volatility: Aggressive
Total Grade: D Industry: Pharmaceuticals: Other

Stock Analysis

Rating: Monthly View

June July August September October November December January February March April May

Rating: Weekly View

This Week: D down no change
Last Week: D same no change
Two Weeks Ago: D up no change
service keys

Lipocine, Inc.© quotemedia

Company Profile

Lipocine Inc., a specialty pharmaceutical company, develops pharmaceutical products using its oral drug delivery technology in the areas of menís and womenís health. The company offers a portfolio of proprietary product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate, LPCN 1021, an oral testosterone replacement therapy designed for twice-a-day dosing, is in Phase III clinical study. The companyís pipeline candidates also include LPCN 1111, a next generation oral testosterone therapy product with once daily dosing that is in Phase II clinical study; and LPCN 1107, which is in Phase I clinical study for the prevention of recurrent preterm birth. Lipocine Inc. is headquartered in Salt Lake City, Utah.